AU2021400845A1 - Dsg2 compositions and methods for the treatment of covid-19 - Google Patents

Dsg2 compositions and methods for the treatment of covid-19 Download PDF

Info

Publication number
AU2021400845A1
AU2021400845A1 AU2021400845A AU2021400845A AU2021400845A1 AU 2021400845 A1 AU2021400845 A1 AU 2021400845A1 AU 2021400845 A AU2021400845 A AU 2021400845A AU 2021400845 A AU2021400845 A AU 2021400845A AU 2021400845 A1 AU2021400845 A1 AU 2021400845A1
Authority
AU
Australia
Prior art keywords
dsg2
isolated polypeptide
covid
protein
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021400845A
Other languages
English (en)
Inventor
Shi Yin Foo
Ryan Edward TYLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arvada Therapeutics Inc
Original Assignee
Arvada Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvada Therapeutics Inc filed Critical Arvada Therapeutics Inc
Publication of AU2021400845A1 publication Critical patent/AU2021400845A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2021400845A 2020-12-15 2021-12-15 Dsg2 compositions and methods for the treatment of covid-19 Pending AU2021400845A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063125583P 2020-12-15 2020-12-15
US63/125,583 2020-12-15
US202163274715P 2021-11-02 2021-11-02
US63/274,715 2021-11-02
PCT/US2021/063433 WO2022132854A1 (en) 2020-12-15 2021-12-15 Dsg2 compositions and methods for the treatment of covid-19

Publications (1)

Publication Number Publication Date
AU2021400845A1 true AU2021400845A1 (en) 2023-07-13

Family

ID=79425717

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021400845A Pending AU2021400845A1 (en) 2020-12-15 2021-12-15 Dsg2 compositions and methods for the treatment of covid-19

Country Status (9)

Country Link
EP (1) EP4263588A1 (enExample)
JP (1) JP2024500250A (enExample)
KR (1) KR20230120141A (enExample)
AU (1) AU2021400845A1 (enExample)
CA (1) CA3202364A1 (enExample)
IL (1) IL303444A (enExample)
MX (1) MX2023006704A (enExample)
TW (1) TW202237634A (enExample)
WO (1) WO2022132854A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024005327A (es) * 2021-11-02 2024-05-21 Arvada Therapeutics Inc Composiciones y metodos de dsg2.
CN116458893A (zh) * 2023-04-19 2023-07-21 电子科技大学 一种covid-19后心肌缺血的早期筛查方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100316347B1 (ko) 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
DE10057397A1 (de) 2000-11-18 2002-05-23 Hella Kg Hueck & Co Vorrichtung zur Ölstandsmessung
US20100303723A1 (en) * 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
EP3568697B1 (en) * 2017-01-13 2022-06-29 The Hospital for Sick Children Method for diagnosis of arrhythmogenic right ventricular cardiomyopathy

Also Published As

Publication number Publication date
JP2024500250A (ja) 2024-01-05
CA3202364A1 (en) 2022-06-23
EP4263588A1 (en) 2023-10-25
WO2022132854A1 (en) 2022-06-23
TW202237634A (zh) 2022-10-01
MX2023006704A (es) 2023-06-20
KR20230120141A (ko) 2023-08-16
IL303444A (en) 2023-08-01

Similar Documents

Publication Publication Date Title
US9932377B2 (en) Mitochondrial targeting and therapeutic use thereof
CN107921085B (zh) 用于治疗衰老相关病症的方法和组合物
ES2426352T3 (es) Uso de la endoglucosidasa EndoS para el tratamiento de enfermedades mediadas por la inmunoglobulina G
US20180112193A1 (en) Csf1 therapeutics
EA009938B1 (ru) ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β
US10034915B2 (en) Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia
EP4263588A1 (en) Dsg2 compositions and methods for the treatment of covid-19
CN111423502A (zh) 多肽、其衍生物及其在制备抗肺纤维化的药物中的应用
KR102569658B1 (ko) 컨쥬게이트 c1 에스테라제 억제제 및 그의 용도
US20240279304A1 (en) Dsg2 compositions and methods
US20240043495A1 (en) Dsg2 compositions and methods for the treatment of covid-19
AU2013344973B2 (en) Compositions and methods for the treatment of ectodermal dysplasia
CN116648255A (zh) 用于治疗covid-19的dsg2组合物和方法
EP3539561A1 (en) Therapeutic agent for cerebral infarction
JP2015140322A (ja) 関節リウマチまたはその関連疾患の予防または治療剤
US20250276047A1 (en) Methods of treating diseases associated with traumatic brain injury
US20240299505A1 (en) Composition for improving, preventing or treating inflammatory bowel disease comprising nampt-derived peptide as active ingredient
WO2022020544A1 (en) Method of treating an inflammatory condition
PT91500A (pt) Processo para a preparacao de antigenio de nefrite clonado
JPH07508733A (ja) 白血病抑制因子結合蛋白
HK1223556B (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis